source
- Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trialAt the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…
- Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to KeytrudaAkeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…Endpoints · 15d agoPositive readoutPositive